Differential exoprotease activities confer tumor-specific serum peptidome patterns
J. Clin. Invest. Josep Villanueva, et al. 116:271 doi:10.1172/JCI26022 [Go to this article.]

Figure 6
Serum peptide signatures for advanced prostate, bladder, and breast cancer. This table contains the same 69 entries as in Figure 5 plus additional details on the identified peptides (listed as m/z values), MS ion intensities, and signatures. The significance levels of 3 different Mann-Whitney U tests (columns 6–8) and of a multiclass Kruskal-Wallis test (column 9) are given. The actual signatures (blue, green, or red) are composed of entries that showed clear peptide ion marker potential (adjusted P < 0.0002) for at least 1 type of cancer. Adjusted P value is the overriding criterion, leading to final signatures of 26 (prostate), 50 (bladder), and 25 (breast) peptide ions (identical to those shown in Figure 5). The second column lists median intensities of each m/z peak in the control samples. Peak intensity ratios (columns 3–5) were calculated by dividing the median values of each m/z peak in each cancer group by the median value of the corresponding peak in the control samples. Ratios (r) for those peptides that are part of 1 or more signatures are shaded dark grey when the median signal is of higher intensity in a particular cancer (r ≥ 1.4) and lighter gray when it is lower (r ≤ 0.75). Norm., normalized.